Concord Drugs Balance Sheet Annual

BSE: - | NSE: - | ISIN: - | Sector: -

86.00 +3.61 (4.38%)Updated : 17 Apr 2026

Interim Data

Annual Data

Fiscal Period	2025	2024	2023	2022
Period End Date	Mar 25	Mar 24	Mar 23	Mar 22
Total Liabilities Shareholders' Equity	65.14	58.81	58.23	56.45
Other Liabilities Total	2.90	2.53	2.46	2.08
Long Term Debt	1.32	0.65	1.91	2.48
Common Stock Total	10.00	10.00	9.32	8.74
Other Current Assets Total	1.54	1.64	7.34	1.38
Total Assets	65.14	58.81	58.23	56.45
Current Portof LT Debt/ Capital Leases	17.92	16.87	15.05	13.95
Cash	0.23	0.18	0.10	0.07
Total Equity	34.11	33.82	31.70	28.36
Long Term Investments	1.44	1.48	1.53	0.64
Retained Earnings( Accumulated Deficit)	24.11	23.82	22.39	19.62
Total Common Shares Outstanding	1.00	1.00	0.93	0.87
Tangible Book Valueper Share Common Eq	34.11	33.82	34.03	32.44
Total Liabilities	31.03	24.99	26.53	28.08
Total Debt	19.24	17.52	16.96	16.43
Short Term Investments	0.12	0.05	0.14	0.10
Cashand Short Term Investments	0.35	0.22	0.24	0.17
Total Receivables Net	13.60	19.83	15.81	22.86
Notes Payable/ Short Term Debt	0.00	0.00	0.00	0.00
Deferred Income Tax	0.63	0.47	0.54	0.66
Accounts Receivable- Trade Net	13.60	19.83	15.81	22.86
Property/ Plant/ Equipment Total- Net	13.57	12.67	13.20	13.88
Total Current Liabilities	26.18	21.34	21.61	22.86
Total Inventory	25.27	22.92	20.06	17.49
Accounts Payable	7.62	3.44	5.27	7.18
Other Currentliabilities Total	0.64	1.03	1.29	1.73
Total Long Term Debt	1.32	0.65	1.91	2.48
Other Long Term Assets Total	0.00	-	0.00	-
Note Receivable- Long Term	9.37	0.04	0.04	0.03
period Length	0.00	0.00	0.00	0.00
Total Current Assets	40.76	44.61	43.46	41.89
Other Equity Total	-	-	0.00	-